source
- FDA launches Rare Disease Framework Initiative to reshape drug development for small patient populationsThe FDA announced a new Rare Disease Framework Initiative aimed at overhauling how drugs and biologics for rare conditions are developed. The initiative will produce a tailored framework that refl…
- FDA approves Emcitate for peripheral thyrotoxicosis in patients with MCT8 deficiencyThe U.S. Food and Drug Administration announced approval of Emcitate (tiratricol) tablets formulated for oral suspension to treat peripheral thyrotoxicosis in patients with MCT8 deficiency, also ca…fda press · 21d agoApprovalPositive